ERBB2 and cancer: Antibody-dependent cytotoxicity assays showed enhanced activity of margetuximab against HER2+ cancer cells when compared with trastuzumab surrogates in donors with a low-affinity variant of FcγRIIIa (158F, homozygous or heterozygous)27.